Novel fluorescencein situhybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Maintenance Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer: Do We Finally Know the Best Schedule?

(2012) J. Alfred Witjes   EUROPEAN UROLOGY

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

(2012) Jorg Oddens et al.   EUROPEAN UROLOGY

Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial

(2012) Ashish M. Kamat et al.   JOURNAL OF UROLOGY

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review

(2011) Sven van den Bosch et al.   EUROPEAN UROLOGY

EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update

(2011) Marko Babjuk et al.   EUROPEAN UROLOGY

Fluorescence in situ hybridization for detecting urothelial carcinoma

(2010) Nancy P. Caraway et al.   CANCER CYTOPATHOLOGY